nab-paclitaxel/rituximab nanoparticle (AR160) / Sorrento, Mayo Clinic - LARVOL DELTA

A First in Human Phase I Trial (LS1681) of Abraxane/Rituximab 160 Nm Nanoparticle (AR160) in Relapsed Refractory B-Cell Lymphomas Including Transformed Follicular Lymphoma: A Final Report (ASH 2023) - "AR160 therapy is a novel drug delivery system incorporating significantly lower doses of paclitaxel and rituximab that is safe and demonstrates promising clinical activity in patients with low-grade and high-grade previously treated B-cell lymphomas. This principle of treatment is applicable to other disorders. Further clinical testing is warranted in these patient populations."

First-in-human • P1 data • Anorexia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Gastrointestinal Disorder • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Mantle Cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • BCL2 • CD20

Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial (clinicaltrials.gov) - P1 | N=18 | Suspended | Sponsor: Mayo Clinic | Trial primary completion date: Apr 2023 ➔ Oct 2023

Trial primary completion date • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • CD20

Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial (clinicaltrials.gov) - P1 | N=9 | Completed | Sponsor: Mayo Clinic | Suspended ➔ Completed | N=18 ➔ 9 | Trial completion date: Apr 2024 ➔ May 2023 | Trial primary completion date: Oct 2023 ➔ May 2023

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • CD20

Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial (clinicaltrials.gov) - P1 | N=18 | Suspended | Sponsor: Mayo Clinic | Trial completion date: Jun 2023 ➔ Apr 2024 | Recruiting ➔ Suspended

Trial completion date • Trial suspension • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • CD20